As the Executive Director of the Infectious Disease Research Center (IDRC), Dr. Goodrich has responsibility for oversight of the Biopharmaceutical Manufacturing and Academic Resource Center (BioMARC) and the Research Innovation Center (RIC). BioMARC is an FDA-inspected not-for-profit service entity that specializes in the production of biologic products that require high containment facilities. The RIC facility houses faculty and private industry research programs requiring biocontainment and general laboratory support environments.
Dr. Goodrich’s research has focused on the study of transfusion transmitted infections and the development of methods for the prevention of transfusion transmitted disease. He has engaged in research on the role of donor white blood cells in the development of graft versus host disease and alloimmunization responses in transfusion recipients. His research has been focused on the development of methods to prevent adverse reactions to blood transfusion.
Ph.D. Chemistry, California Institute of Technology, Pasadena, California, 1990B.S. Chemistry, The Ohio State University, Columbus, Ohio, 1985
CA Tormey, M Santhanakrishnan, NH Smith, J Liu, S Marschner, R. Goodrich (2016) Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells; Transfusion, 56(4):863-72AP Cap, HF Pidcoke, SD Keil, HM Staples, M Anantpadma, R Carrion, R. Goodrich (2016) Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro; Transfusion 56 (S1), S6-S15 JP Allain, AK Owusu-Ofori, SM Assennato, S Marschner, RP Goodrich, S Owusu-Ofori (2016) Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: The African Investigation of the Mirasol System (AIMS) randomised controlled trial; The Lancet: 387 (10029), 1753-1760.Schubert, P., Culibrk, B., Karwal, S., Goodrich, R.P., Devine, D.V. (2016) Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment. Proteomics Clinical Applications; 10, 839-850.Faddy, H.M., Fryk, J.J., Watterson, D., Young, P.R., Modhirin, N., Muller, D.A., Keil, S.D., Goodrich, R.P., and Marks, D.C. (2016) Riboflavin and Ultraviolet Light: Impact on Dengue Virus Infectivity. Vox Sanguinis; 111, 235–241.Muench MO, Heitman JW, Inglis H, Fomin ME, Marschner S, Goodrich RP, Norris PJ, Jackman RP. (2016) Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets; Transfusion; 56 (6): 1419-1429Allain JP, Assennato SM, Osei EN, Owusu-Ofori AK, Marschner S, Goodrich RP, Owusu-Ofori S. (2016) Characterization of post-transfusion Plasmodium falciparum infection in semi-immune nonparasitemic patients. Transfusion; doi: 10.1111/trf.13706. Epub ahead of print.Jackman, R.P., Muench, M.O., Inglis, H., Heitman, J.W., Marschner, S., Goodrich,
R.P., and Norris, P.J. (2016) Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood. Transfusion; doi:10.1111/trf.13895. Epub ahead of print.
Yonemura, S., Doane, S., Keil, S., Goodrich, R., Pidcoke, H., Cardoso, M. (2017) Improving the safety of whole blood-derived transfusion products with a riboflavin-based pathogen reduction technology. Blood Transfusion; doi: 10.2450/2017.0320-16. Epub ahead of print.Makdoumi, K., Goodrich, R.P., Backman, A. (2017) Photochemical eradication of MRSA by blue light activated riboflavin. Acta Opthalmologica; In Press.Cancelas, J., Slicther, S., Rugg, N., Pratt, P., Gayle, U., Nestheide, S., Corson, J., Pellham, E., Huntington, M., Goodrich, R. (2017) Red blood cells derived from whole blood treated with riboflavin/UV maintain adequate survival in vivo after 21 days of storage. Transfusion; In Press.
Agents associated with transfusion transmitted diseases, including bacterial, parasitic and viral pathogens.